Cue Biopharma, INC

Cue Biopharma, Inc. has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026, bringing extensive experience in biopharmaceutical finance.

Cue Biopharma announced a $50 million private placement of common stock and pre-funded warrants to accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to fund clinical development.

Cue Biopharma's stockholders approved the 2026 Stock Incentive Plan and the issuance of shares related to a licensing deal at a special meeting on June 1, 2026.

Cue Biopharma has announced significant changes to its Board of Directors and executive leadership, including the appointment of a new Chief Legal & Compliance Officer and Principal Accounting Officer, and the addition of two new directors.

Cue Biopharma announced first quarter 2026 financial results, highlighting strategic pipeline enhancements, a significant private placement, and leadership changes.

Cue Biopharma announced a 1-for-30 reverse stock split effective April 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Cue Biopharma's Q1 2026 report details significant collaboration revenue growth and strategic advancements in its drug candidate pipeline, alongside ongoing efforts to secure future funding.

Cue Biopharma reports Q3 2025 results, highlighting a net loss of $7.4 million, reduced R&D expenses, and new collaborations while facing substantial doubt about its ability to continue as a going concern.

Cue Biopharma reported a reduced net loss and secured a significant collaboration with Boehringer Ingelheim, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid deficiency.

Cue Biopharma announces its Q1 2025 financial results, emphasizing a new collaboration with Boehringer Ingelheim and ongoing efforts to secure additional funding amidst going concern uncertainties.

Cue Biopharma announced its third quarter 2024 results, highlighting a strategic shift towards autoimmune programs while continuing to monitor oncology assets.

Cue Biopharma shifts focus to autoimmune programs while reporting a net loss of $22.5 million for the first half of 2024, alongside ongoing clinical trial progress.

Cue Biopharma reports recurring losses and going concern doubt, while advancing its autoimmune pipeline with CUE-401 nearing IND filing and CUE-501 licensed to Boehringer Ingelheim, alongside oncology asset licensing.

Cue Biopharma shifts focus to autoimmune drug candidates while exploring strategic partnerships for its oncology programs, according to its 2024 annual report.

Cue Biopharma's 10-K filing outlines the details of its common stock, preferred stock, and various anti-takeover provisions designed to protect the company from hostile acquisitions.

James M Ahlers, Chief Financial Officer of Cue Biopharma, Inc., reported multiple transactions in common stock on July 30, 2026.

Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., reported multiple transactions in common stock on June 1, 2026.

Dominique Christian Borie, Chief Medical Officer of Cue Biopharma, Inc., reported multiple transactions in common stock on July 13, 2026.

Pamela Garzone, a Director at Cue Biopharma, Inc., has been granted 21,800 Restricted Stock Units (RSUs) vesting over three years.

Cue Biopharma reports a restricted stock unit grant to Director Daniel A. Camardo, with vesting over three years.

Cue Biopharma reports a restricted stock unit grant to Director Pasha Sarraf, with vesting over three years.

Cue Biopharma is holding a special meeting on June 1, 2026, to seek stockholder approval for the issuance of shares upon warrant exercise related to a licensing deal and private placement, and to approve its 2026 Stock Incentive Plan.

Cue Biopharma, Inc. is seeking stockholder approval for a reverse stock split at a ratio between 1-for-30 and 1-for-50 to maintain its Nasdaq listing and enhance investor appeal.

Cue Biopharma, Inc. has issued a supplement to its proxy statement, disagreeing with Institutional Shareholder Services' recommendation against its 2025 Stock Incentive Plan, asserting ISS double-counted shares and inflated plan cost.

Cue Biopharma's upcoming annual meeting on June 4, 2025, will include proposals to increase authorized shares, elect board members, ratify the accounting firm, approve executive compensation, and adopt a new stock incentive plan.

Cue Biopharma is asking stockholders to approve an amendment to increase authorized shares and a new stock incentive plan at its virtual annual meeting on June 4, 2025.

Cue Biopharma is asking stockholders to approve an amendment to their corporate charter to increase the number of authorized shares, providing flexibility for future financing and strategic opportunities.

Mark E. Strome and affiliated entities have filed an amended Schedule 13G, revealing a collective beneficial ownership of 4.99% of Cue Biopharma, Inc.'s common stock, affirming a passive investment intent.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have filed an amended Schedule 13G, confirming their continued beneficial ownership of 9.99% of Cue Biopharma, Inc.'s common stock as of March 19, 2025.

Slate Path Capital LP and David Greenspan have filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% in Cue Biopharma, Inc., primarily through shares issuable upon warrant exercise.